Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HPT014
MIFTS: 49

Hepatorenal Syndrome

Categories: Rare diseases, Gastrointestinal diseases, Nephrological diseases, Endocrine diseases, Liver diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Hepatorenal Syndrome

About this section

MalaCards integrated aliases for Hepatorenal Syndrome:

Name: Hepatorenal Syndrome 12 76 53 55 44 15 73
Hepato-Renal Syndrome 53

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Gastrointestinal diseases Nephrological diseases Endocrine diseases Liver diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:11823
ICD10 33 K76.7
ICD9CM 35 572.4
MeSH 44 D006530
NCIt 50 C113400
SNOMED-CT 68 51292008
UMLS 73 C0019212
Sources

Summaries for Hepatorenal Syndrome

About this section
NIH Rare Diseases : 53 Hepatorenal syndrome is a form of impaired kidney function that occurs in individuals with advanced chronic liver disease. As many as 40% of individuals with cirrhosis and ascites will develop hepatorenal syndrome. Symptoms may include fatigue, abdominal pain, and a general feeling of ill health (malaise). There are two distinct types of hepatorenal syndrome. Type I progresses quickly (within days), leading to kidney failure. Individuals with type I typically have dramatically reduced urine output, edema, and jaundice, and often suffer from hepatic encephalopathy. Type II progresses more slowly, over weeks or months, and the symptoms are less severe. The cause of hepatorenal syndrome is unknown. A contributing factor seems to be a narrowing of the blood vessels that connect into the kidneys. This causes a decrease in blood flow to the kidneys, impairing their function. In some cases, triggers or precipitating factors (infections, blood loss from the gastrointestinal tract, low blood pressure) are involved. Treatment is aimed at helping the liver work better and maintaining kidney function. In many cases, a liver transplant is needed. In some cases, individuals also need a kidney transplant. 

MalaCards based summary : Hepatorenal Syndrome, also known as hepato-renal syndrome, is related to hepatic coma and esophageal varix. An important gene associated with Hepatorenal Syndrome is ALB (Albumin), and among its related pathways/superpathways are FOXA2 and FOXA3 transcription factor networks and IL1 and megakaryocytes in obesity. The drugs Terlipressin and Adefovir Dipivoxil have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and testes, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 76 Hepatorenal syndrome (often abbreviated HRS) is a life-threatening medical condition that consists of... more...

Sources

Related Diseases for Hepatorenal Syndrome

About this section

Diseases related to Hepatorenal Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 166)
# Related Disease Score Top Affiliating Genes
1 hepatic coma 30.5 ALB F2
2 esophageal varix 30.5 ALB F2
3 acute liver failure 30.5 ALB F2
4 compartment syndrome 30.4 ALB F2
5 hepatitis a 30.3 ALB F2
6 hepatopulmonary syndrome 30.2 ALB EDN1
7 portal hypertension 30.0 ALB EDN1 F2
8 eclampsia 30.0 ALB EDN1 F2
9 obstructive jaundice 29.7 ALB EDN1 F2 REN
10 pulmonary edema 28.5 ACE EDN1 F2 REN
11 acute kidney tubular necrosis 28.5 ALB CST3 IL18 NAGLU NPPA
12 liver cirrhosis 28.4 ALB AQP2 EDN1 F2 NPPA REN
13 pulmonary hypertension 28.3 ACE EDN1 NPPA REN
14 pre-eclampsia 27.5 CST3 EDN1 F2 IL18 NPPA REN
15 peroxisome biogenesis disorder 1a 11.1
16 joubert syndrome with oculorenal anomalies 11.1
17 benign essential hypertension 10.8 ALB REN
18 kidney papillary necrosis 10.8 ALB REN
19 antipyrine metabolism 10.7 ALB F2
20 non-a-e hepatitis 10.7 ALB F2
21 malignant renovascular hypertension 10.7 EDN1 REN
22 malignant secondary hypertension 10.7 EDN1 REN
23 fournier gangrene 10.7 ALB F2
24 perinephritis 10.7 EDN1 REN
25 abdominal tuberculosis 10.7 ALB F2
26 intestinal impaction 10.7 F2 REN
27 kwashiorkor 10.7 ALB F2
28 hepatic tuberculosis 10.7 ALB F2
29 splenic disease 10.7 ALB F2
30 renal tuberculosis 10.7 EDN1 REN
31 ascending cholangitis 10.7 ALB F2
32 chronic thromboembolic pulmonary hypertension 10.7 EDN1 F2
33 cardiac tamponade 10.6 F2 REN
34 hypersplenism 10.6 ALB F2
35 hemorrhagic fever 10.6 ALB F2
36 choledocholithiasis 10.6 ALB F2
37 postural hypotension 10.6 NPPA REN
38 analbuminemia 10.6 ALB F2
39 dysfibrinogenemia 10.6 ALB F2
40 hepatitis e 10.5 ALB F2
41 acute poststreptococcal glomerulonephritis 10.5 EDN1 NPPA
42 apnea, obstructive sleep 10.5 EDN1 REN
43 vein disease 10.5 ALB F2
44 korean hemorrhagic fever 10.5 F2 NPPA
45 noma 10.5 ALB IL18
46 bile duct disease 10.4 ALB F2
47 acute cystitis 10.4 ALB IL18
48 lipoid nephrosis 10.4 ALB NAGLU
49 inappropriate adh syndrome 10.4 AQP2 REN
50 acute pyelonephritis 10.4 ALB NAGLU

Comorbidity relations with Hepatorenal Syndrome via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Alcoholic Liver Cirrhosis
Chronic Kidney Failure Deficiency Anemia
Heart Disease Hepatic Encephalopathy
Portal Hypertension

Graphical network of the top 20 diseases related to Hepatorenal Syndrome:



Diseases related to Hepatorenal Syndrome
Sources

Symptoms & Phenotypes for Hepatorenal Syndrome

About this section

MGI Mouse Phenotypes related to Hepatorenal Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.97 EDN1 F2 IL18 ACE NAGLU NPPA
2 homeostasis/metabolism MP:0005376 9.91 EDN1 F2 IL18 ACE ALB NPPA
3 hematopoietic system MP:0005397 9.87 REN F2 IL18 ACE NAGLU NPPA
4 mortality/aging MP:0010768 9.81 REN CST3 EDN1 F2 IL18 ACE
5 muscle MP:0005369 9.43 REN CST3 EDN1 IL18 ALB NPPA
6 renal/urinary system MP:0005367 9.17 EDN1 ACE NAGLU ALB NPPA AQP2
Sources

Drugs & Therapeutics for Hepatorenal Syndrome

About this section

Drugs for Hepatorenal Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 161)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Terlipressin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 14636-12-5 72081
2
Adefovir Dipivoxil Approved, Investigational Phase 4 142340-99-6 60871
3
Telbivudine Approved, Investigational Phase 4 3424-98-4 159269
4
Norfloxacin Approved Phase 4 70458-96-7 4539
5
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
6
Tranexamic Acid Approved Phase 4 1197-18-8 5526
7
Carvedilol Approved, Investigational Phase 4,Not Applicable 72956-09-3 2585
8
Adefovir Investigational Phase 4 106941-25-7
9 Antihypertensive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
10 Coagulants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
11 Hemostatics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
12 Lypressin Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
13 Natriuretic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
14 Vasoconstrictor Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
15 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Not Applicable
16 Anti-Retroviral Agents Phase 4
17 Antiviral Agents Phase 4,Phase 2
18 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
20 Reverse Transcriptase Inhibitors Phase 4
21 Adrenergic Agents Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
22 Adrenergic Antagonists Phase 4,Phase 3,Not Applicable
23 Adrenergic beta-Antagonists Phase 4,Phase 3,Not Applicable
24 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
25 Vasodilator Agents Phase 4,Phase 3,Not Applicable
26 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Not Applicable
27 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
28 Cytochrome P-450 Enzyme Inhibitors Phase 4
29 Topoisomerase Inhibitors Phase 4
30 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 3,Not Applicable
31 Antifibrinolytic Agents Phase 4
32 Adrenergic alpha-1 Receptor Antagonists Phase 4
33 Adrenergic alpha-Antagonists Phase 4
34 Anticoagulants Phase 4,Not Applicable
35 Blood Substitutes Phase 4
36 Dextrans Phase 4
37 Plasma Substitutes Phase 4
38
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2,Not Applicable 83-43-2 6741
39
Pentoxifylline Approved, Investigational Phase 3,Not Applicable 6493-05-6 4740
40
Prednisolone Approved, Vet_approved Phase 3,Phase 2,Not Applicable 50-24-8 5755
41
Propranolol Approved, Investigational Phase 3,Not Applicable 525-66-6 4946
42
Midodrine Approved Phase 2, Phase 3,Phase 3,Not Applicable 133163-28-7, 42794-76-3 4195
43
Octreotide Approved, Investigational Phase 2, Phase 3,Phase 3,Not Applicable 83150-76-9 383414 6400441
44
Norepinephrine Approved Phase 3,Phase 2,Early Phase 1,Not Applicable 51-41-2 439260
45
Mannitol Approved, Investigational Phase 3 69-65-8 453 6251
46
Dopamine Approved Phase 2, Phase 3 51-61-6, 62-31-7 681
47
Furosemide Approved, Vet_approved Phase 2, Phase 3 54-31-9 3440
48
Spironolactone Approved Phase 2, Phase 3 1952-01-7, 52-01-7 5833
49
Tolvaptan Approved Phase 2, Phase 3 150683-30-0 216237
50
Lenograstim Approved, Investigational Phase 2, Phase 3,Not Applicable 135968-09-1

Interventional clinical trials:

(show top 50) (show all 93)
# Name Status NCT ID Phase Drugs
1 The Effect of Terlipressin in the Prevention of Type 2 Hepatorenal Syndrome by Improving Mean Arterial Pressure Unknown status NCT02489864 Phase 4 Terlipressin
2 Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial Unknown status NCT01799486 Phase 4 Telbivudine;Enecavir;Adefovir
3 Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis Completed NCT00359853 Phase 4 Oral norfloxacin
4 Norfloxacin Versus Ciprofloxacin for Spontaneous Bacterial Peritonitis (SBP) Prevention Completed NCT01542801 Phase 4 Norfloxacin;ciprofloxacin
5 Efficacity and Safety of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding Recruiting NCT03023189 Phase 4 Tranexamic acid;Placebo
6 Early Precise Diagnosis and Intervention of CPT Based on a Noninvasive 3D-vHPS Recruiting NCT02925975 Phase 4 Carvedilol
7 Treatment of Hepatorenal Syndrome With Terlipressin Infusion Adjusted to Hemodynamic Response Active, not recruiting NCT01530711 Phase 4 Terlipressin and albumin
8 Treatment of Hepatorenal Syndrome With Terlipressin Plus Albumin vs Albumin Suspended NCT00287664 Phase 4 terlipressin
9 The INFECIR-2 Albumin Prevention Study Terminated NCT02034279 Phase 4 Albumin
10 Clinical, Inflammatory, and Economic Impact of Dextran 70 in Treating Spontaneous Bacterial Peritonitis Terminated NCT00570960 Phase 4 Dextran 70
11 Terlipressin Given As I.V. Boluses Versus Terlipressin Given As Continuous Intravenous Infusion In Patients With Cirrhosis And Type 1 Hepatorenal Syndrome Unknown status NCT00742690 Phase 2, Phase 3 terlipressin given by intravenous boluses and albumin;terlipressin given by continuous intravenous infusion and albumin
12 Short-term Survival in Patients With Severe Alcoholic Hepatitis Treated With Steroid Versus Pentoxifylline Unknown status NCT01455337 Phase 3 pentoxifylline;Prednisolone
13 To Study the Effect of Nonselective Beta Blockers in Advanced Stage Liver Disease With Ascites Unknown status NCT02649335 Phase 3 Propranolol
14 Study of Terlipressin Versus Placebo to Treat Hepatorenal Syndrome Type 1 Completed NCT00089570 Phase 3 terlipressin;Placebo
15 Noradrenalin vs Terlipressin in Hepatorenal Syndrome Completed NCT00370253 Phase 3 Terlipressin;Noradrenalin
16 A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin Completed NCT01143246 Phase 3 Terlipressin;Placebo
17 TYPE 2 HEPATORENAL SYNDROME Completed NCT01637454 Phase 3 Noradrenaline;Terlipressin
18 The Use of Drugs to Improve Kidney Function in Patients With Liver and Kidney Dysfunction Completed NCT00240045 Phase 2, Phase 3 Midodrine, albumin, octreotide LAR;midodrine, octreotide, albumin
19 Terlipressin in Septic Shock in Cirrhosis Completed NCT00628160 Phase 2, Phase 3 Terlipressin;alpha adrenergic drugs
20 Role of Midodrine and Tolvaptan in Patients With Cirrhosis With Refractory or Recurrent Ascites Completed NCT02173288 Phase 2, Phase 3 Standard medical therapy;Tolvaptan;Midodrine
21 Efficacy and Safety of Viusid in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection. Completed NCT00502086 Phase 3
22 Granulocyte Colony Stimulating Factor And Growth Hormone In Cirrhosis Of Liver: An Open Label Study Completed NCT02451033 Phase 2, Phase 3 standard medical therapy;G-CSF;Growth Hormone
23 CNI-free de Novo Protocol in Patients Undergoing Liver Transplantation With Renal Impairment Completed NCT00604357 Phase 3 anti-CD 25 mAb, Sirolimus, MMF
24 Double-blind Randomized Controlled Trial in Severe Alcoholic Hepatitis Completed NCT01214226 Phase 3 Pentoxifylline;placebo
25 Effects of Propofol on Oxidative Stress and Liver Regeneration After Partial Hepatectomy Completed NCT00219856 Phase 3 Propofol;Penthotal;Desflurane
26 Norepinephrine Infusion Versus Midodrine & Octreotide in Patients With Hepatorenal Syndrome Type 1. Recruiting NCT03455322 Phase 2, Phase 3 norepinephrine versus midodrine & octreotide
27 A Study To Confirm Efficacy and Safety of Terlipressin in HRS Type 1 Recruiting NCT02770716 Phase 3 Terlipressin acetate
28 Safety Use of ATeGe in Liver Transplant Recipients With Pre-transplant Renal Dysfunction Recruiting NCT01453218 Phase 3 ATeGe-Fresenius
29 Efficacy of Antibiotic Therapy in Severe Alcoholic Hepatitis Treated With Prednisolone Recruiting NCT02281929 Phase 3 Amoxicillin;Placebo;Prednisolone
30 Hepatic Venous Pressure Gradient-guided Versus Standard Beta-blocker Therapy in Primary Prevention of Variceal Bleeding Recruiting NCT01618890 Phase 3
31 Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites Not yet recruiting NCT03069131 Phase 3 Rifaximin
32 Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome Terminated NCT00742339 Phase 2, Phase 3 Terlipressin plus albumin;Midodrine plus octreotide plus human albumin
33 Secondary Prophylaxis of Gastrointestinal Bleeding in Cirrhotic Patients Using THALIDOMIDE Withdrawn NCT00787436 Phase 3 Thalidomide
34 Midodrine, Octreotide and Albumin: Impact on Renal Function of Patients With Liver Cirrhosis and Renal Failure Unknown status NCT01587222 Phase 2 Albumin;Midodrine;Octreotide
35 Low-dose Albumin Solution in SBP: a Randomized Double-blind Pilot Study Unknown status NCT00852800 Phase 2 Albumin;Albumin
36 UC-MSC Infusion for HBV-Related Acute-on-Chronic Liver Failure Unknown status NCT02812121 Phase 2 umbilical cord blood mesenchymal stem cells
37 Adrenal Insufficiency in Cirrhotics With Ascites. Effects of Hydrocortisone on Renal and Haemodynamic Function Unknown status NCT00657306 Phase 2 hydrocortisone;dextrose solution 5%
38 Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients Completed NCT01436500 Phase 2 Ifetroban Injection;Placebo
39 A Study of Terlipressin in Patients With Hepatorenal Syndrome Type 1 Completed NCT01373606 Phase 1, Phase 2 Terlipressin
40 Single Pass Albumin Dialysis in Patients With Cirrhosis Completed NCT00764049 Phase 1, Phase 2
41 A Phase II, Double-blinded, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Vitalliver in Patients With Decompensated Cirrhosis Completed NCT00562783 Phase 2 Vitaliver;Placebo
42 The Efficacy and Safety of Entecavir Treatment of Patients With Acute on Chronic Hepatitis B Liver Failure Completed NCT01254994 Phase 2 entecavir;Traditional comprehensive medical treatment
43 Midodrine and Albumin for Cirrhotic Patients With Functional Renal Impairment Completed NCT01133795 Phase 2 Midodrine plus Albumin
44 Selonsertib in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH) Completed NCT02854631 Phase 2 Selonsertib;Prednisolone;Placebo
45 Effects of Rifaximin in Patients With Acute Alcoholic Hepatitis Enrolling by invitation NCT02116556 Phase 2 Prednisone;Rifaximin
46 A Phase 1 Study of LJPC-501 in Patients With Hepatorenal Syndrome Terminated NCT01906307 Phase 1 LJPC-501
47 Evaluation of Renal Blood Flow Using Contrast Enhanced Ultrasound for Differential Diagnosis of Acute Kidney Injury in Cirrhotic Patients: A Pilot Study Unknown status NCT02147470 Not Applicable Definity ultrasound contrast agent
48 Prognosis Scoring System for Acute-on-Chronic Liver Failure Unknown status NCT01961440
49 Comparative Analysis of Different Tests to Evaluate Prognosis of Patients on Liver Transplant Waiting List Unknown status NCT01774617 Not Applicable
50 Treatment of Type-1 Hepatorenal Syndrome Associated With Sepsis Completed NCT01932151 Not Applicable Terlipressin and albumin

Search NIH Clinical Center for Hepatorenal Syndrome

Cochrane evidence based reviews: hepatorenal syndrome

Sources

Genetic Tests for Hepatorenal Syndrome

About this section
Sources

Anatomical Context for Hepatorenal Syndrome

About this section

MalaCards organs/tissues related to Hepatorenal Syndrome:

41
Liver, Kidney, Testes, Bone, Skin, Bone Marrow, Neutrophil
Sources

Publications for Hepatorenal Syndrome

About this section

Articles related to Hepatorenal Syndrome:

(show top 50) (show all 635)
# Title Authors Year
1
Response to Terlipressin in Hepatorenal Syndrome: Predict to Prognosticate! ( 29914639 )
2018
2
Systemic hemodynamic response to terlipressin predicts development of hepatorenal syndrome and survival in advanced cirrhosis. ( 29432366 )
2018
3
Development of an automated phenotyping algorithm for hepatorenal syndrome. ( 29530803 )
2018
4
Hepatorenal syndrome: the clinical impact of vasoactive therapy. ( 29258378 )
2018
5
Oxidative stress, NOx/l-arginine ratio and glutathione/glutathione S-transferase ratio as predictors of 'sterile inflammation' in patients with alcoholic cirrhosis and hepatorenal syndrome type II. ( 29658815 )
2018
6
Disruption of renal arginine metabolism promotes kidney injury in hepatorenal syndrome. ( 29631342 )
2018
7
Predictors of Response to Terlipressin in Hepatorenal Syndrome. ( 29551736 )
2018
8
When Should We Stop Treatment With Terlipressin and Albumin for Patients With Hepatorenal Syndrome? ( 29684461 )
2018
9
A novel scoring model for predicting mortality risk in patients with cirrhosis and hepatorenal syndrome. ( 29634664 )
2018
10
Treatment of Type-1 Hepatorenal Syndrome with Pentoxifylline: A Randomized Placebo Controlled Clinical Trial. ( 29469046 )
2018
11
Circulating miR-21, miR-210 and miR-146a as potential biomarkers to differentiate acute tubular necrosis from hepatorenal syndrome in patients with liver cirrhosis: a pilot study. ( 29303765 )
2018
12
Transjugular intrahepatic portosystemic shunt for hepatorenal syndrome: A systematic review and meta-analysis. ( 29422242 )
2018
13
Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in Patients With Hepatorenal Syndrome. ( 29391267 )
2018
14
Terlipressin in the treatment of hepatorenal syndrome: A systematic review and meta-analysis. ( 29668606 )
2018
15
Hepatorenal syndrome in the era of acute kidney injury. ( 29845739 )
2018
16
Editorial: tackling hepatorenal syndrome-terlipressin for all, or time for a stratified approach? ( 28621082 )
2017
17
Terlipressin versus other vasoactive drugs for hepatorenal syndrome. ( 28953318 )
2017
18
Pharmacological Therapies for Hepatorenal Syndrome: A Systematic Review and Meta-Analysis. ( 28991106 )
2017
19
New Developments in Hepatorenal Syndrome. ( 28602971 )
2017
20
Bile Cast Nephropathy in Patients with Acute Kidney Injury Due to Hepatorenal Syndrome: A Postmortem Kidney Biopsy Study. ( 28660146 )
2017
21
Protective Effects of the Third Generation Vasodilatory I9eta - Blocker Nebivolol against D-Galactosamine - Induced Hepatorenal Syndrome in Rats. ( 29362613 )
2017
22
Induction of renal artery hyperresponsiveness by alpha1-adrenoceptor in hepatorenal syndrome. ( 29312606 )
2017
23
Noradrenaline as an alternative medical treatment to terlipressin in the management of hepatorenal syndrome type 1. ( 29054321 )
2017
24
Association of arginine vasopressin receptor 1a gene polymorphisms with hepatorenal syndrome. ( 28420919 )
2017
25
Hepatorenal syndrome: role of the transjugular intrahepatic stent shunt in real life practice. ( 29151800 )
2017
26
Hepatorenal Syndrome ( 28613606 )
2017
27
Comparative efficacy of vasoconstrictor therapies for type 1 hepatorenal syndrome: a network meta-analysis. ( 28708431 )
2017
28
Portopulmonary hypertension and hepatorenal syndrome. Two faces of the same coin. ( 28583409 )
2017
29
Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis. ( 28403995 )
2017
30
Acute kidney injury in acute-on-chronic liver failure: where does hepatorenal syndrome fit? ( 28844314 )
2017
31
Vasoactive Agents for Hepatorenal Syndrome: A Mixed Treatment Comparison Network Meta-Analysis and Trial Sequential Analysis of Randomized Clinical Trials. ( 28924736 )
2017
32
Terlipressin is superior to midodrine/octreotide for hepatorenal syndrome type 1. ( 29111999 )
2017
33
Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis: a systematic review and meta-analysis. ( 28763340 )
2017
34
Renal dysfunction in cirrhosis: acute kidney injury and the hepatorenal syndrome. ( 28533910 )
2017
35
Baclofen-Related Neurotoxicity: Implication in a Fatality Associated With Hepatorenal Syndrome. ( 28680269 )
2017
36
Long-term rifaximin therapy as a primary prevention of hepatorenal syndrome. ( 28902040 )
2017
37
A Case of Hepatorenal Syndrome and Abdominal Compartment Syndrome with High Renal Congestion. ( 28919595 )
2017
38
Terlipressin for hepatorenal syndrome: ready for prime time. ( 28403987 )
2017
39
Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome. ( 29943803 )
2017
40
The burden of hepatorenal syndrome among commercially insured and Medicare patients in the United States. ( 28509578 )
2017
41
Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1. ( 28052382 )
2017
42
Management of ascites and hepatorenal syndrome. ( 28836115 )
2017
43
Red signs and not severity of cirrhosis should determine non-selective I^-blocker treatment in Child-Pugh C cirrhosis with small varices: increased risk of hepatorenal syndrome and death beyond 6a88months of propranolol use. ( 26935875 )
2016
44
Hepatorenal Syndrome In Patients With Cirrhosis Of Liver According To 2007 International Ascites Club Criteria. ( 28712240 )
2016
45
Evidence-Based Therapeutic Options for Hepatorenal Syndrome. ( 26922867 )
2016
46
Hepatorenal syndrome. ( 27372112 )
2016
47
Serum and urinary biomarkers that predict hepatorenal syndrome in patients with advanced cirrhosis. ( 27876501 )
2016
48
Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study. ( 26659927 )
2016
49
Acute kidney injury in cirrhosis besides hepatorenal syndrome. ( 27727684 )
2016
50
Hepatorenal syndrome in cirrhosis: diagnostic, pathophysiological, and therapeutic aspects. ( 27248461 )
2016
Sources

Variations for Hepatorenal Syndrome

About this section
Sources

Expression for Hepatorenal Syndrome

About this section
Search GEO for disease gene expression data for Hepatorenal Syndrome.
Sources

Pathways for Hepatorenal Syndrome

About this section

Pathways related to Hepatorenal Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
FOXA2 and FOXA3 transcription factor networks 1
10.8 ALB F2
2
IL1 and megakaryocytes in obesity 1
10.35 F2 IL18
3
A-beta Pathways: Plaque Formation and APP Metabolism 65
9.98 ACE CST3
Sources

GO Terms for Hepatorenal Syndrome

About this section

Cellular components related to Hepatorenal Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.7 ACE ALB AQP2 CST3 F2 IL18
2 extracellular region GO:0005576 9.56 ACE ALB CST3 EDN1 F2 IL18
3 extracellular space GO:0005615 9.23 ACE ALB CST3 EDN1 F2 IL18

Biological processes related to Hepatorenal Syndrome according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.67 EDN1 F2 IL18 NPPA
2 response to hypoxia GO:0001666 9.65 CST3 EDN1 NPPA
3 negative regulation of proteolysis GO:0045861 9.51 CST3 F2
4 regulation of vasoconstriction GO:0019229 9.49 ACE EDN1
5 positive regulation of heart rate GO:0010460 9.46 EDN1 NPPA
6 middle ear morphogenesis GO:0042474 9.43 EDN1 NAGLU
7 regulation of blood vessel size GO:0050880 9.4 EDN1 NPPA
8 response to muscle stretch GO:0035994 9.32 EDN1 NPPA
9 amyloid-beta metabolic process GO:0050435 9.26 ACE REN
10 cellular protein metabolic process GO:0044267 9.26 ALB CST3 F2 NPPA
11 angiotensin maturation GO:0002003 9.16 ACE REN
12 regulation of blood pressure GO:0008217 8.92 ACE EDN1 NPPA REN

Molecular functions related to Hepatorenal Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 8.92 EDN1 F2 NPPA REN
Sources

Sources for Hepatorenal Syndrome

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....